| Year |
Citation |
Score |
| 2023 |
Dimitriou NG, Meuth SG, Martinez-Lapiscina EH, Albrecht P, Menge T. Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease. Cns Drugs. 37: 69-92. PMID 36598730 DOI: 10.1007/s40263-022-00977-3 |
0.3 |
|
| 2020 |
Müller-Schmitz K, Krasavina-Loka N, Yardimci T, Lipka T, Kolman AGJ, Robbers S, Menge T, Kujovic M, Seitz RJ. Normal Pressure Hydrocephalus Associated with Alzheimer's Disease. Annals of Neurology. PMID 32662116 DOI: 10.1002/Ana.25847 |
0.466 |
|
| 2019 |
Christl J, Verhülsdonk S, Pessanha F, Menge T, Seitz RJ, Kujovic M, Höft B, Supprian T, Lange-Asschenfeldt C. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 31683478 DOI: 10.3233/Jad-190550 |
0.452 |
|
| 2016 |
Menge T, Dubey D, Warnke C, Hartung HP, Stüve O. Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis. Expert Review of Neurotherapeutics. PMID 27552111 DOI: 10.1080/14737175.2016.1227242 |
0.43 |
|
| 2015 |
Dubey D, Kieseier BC, Hartung HP, Hemmer B, Warnke C, Menge T, Miller-Little WA, Stuve O. Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Review of Neurotherapeutics. 15: 339-46. PMID 25800129 DOI: 10.1586/14737175.2015.1025755 |
0.381 |
|
| 2015 |
Ruttmann A, Schmidt-Kraepelin C, Zielasek J, Menge T, Seitz R, FRCP HH, Gaebel W. Assessing the Intensity and Frequency of Symptoms of Mental Disorders in Patients with Neurological Disorders European Psychiatry. 30: 415. DOI: 10.1016/S0924-9338(15)30330-8 |
0.388 |
|
| 2014 |
Menge T, Stüve O, Kieseier BC, Hartung HP. Alemtuzumab: the advantages and challenges of a novel therapy in MS. Neurology. 83: 87-97. PMID 24920854 DOI: 10.1212/Wnl.0000000000000540 |
0.386 |
|
| 2014 |
Hartung HP, Aktas O, Menge T, Kieseier BC. Immune regulation of multiple sclerosis. Handbook of Clinical Neurology. 122: 3-14. PMID 24507511 DOI: 10.1016/B978-0-444-52001-2.00001-7 |
0.37 |
|
| 2014 |
Rommer PS, Zettl UK, Kieseier B, Hartung HP, Menge T, Frohman E, Greenberg BM, Hemmer B, Stüve O. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clinical and Experimental Immunology. 175: 397-407. PMID 24102425 DOI: 10.1111/Cei.12206 |
0.378 |
|
| 2013 |
Teunissen C, Menge T, Altintas A, Ãlvarez-Cermeño JC, Bertolotto A, Berven FS, Brundin L, Comabella M, Degn M, Deisenhammer F, Fazekas F, Franciotta D, Frederiksen JL, Galimberti D, Gnanapavan S, et al. Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 19: 1802-9. PMID 23695446 DOI: 10.1177/1352458513488232 |
0.327 |
|
| 2013 |
Warnke C, Meyer Zu Hörste G, Menge T, Stüve O, Hartung HP, Wiendl H, Kieseier BC. Teriflunomide for treatment of multiple sclerosis | Teriflunomid zur Behandlung der Multiplen Sklerose Nervenarzt. 84: 724-731. PMID 23695001 DOI: 10.1007/S00115-013-3779-7 |
0.396 |
|
| 2012 |
Weber MS, Menge T, Lehmann-Horn K, Kronsbein HC, Zettl U, Sellner J, Hemmer B, Stüve O. Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects. Current Pharmaceutical Design. 18: 209-19. PMID 22229582 DOI: 10.2174/138161212799040501 |
0.405 |
|
| 2012 |
Menge T, Kieseier BC. Alemtuzumab: Current Concepts and Application for the Treatment of Multiple Sclerosis International Journal of Clinical Reviews. DOI: 10.5275/Ijcr.2012.04.06 |
0.312 |
|
| 2012 |
Menge T, Meyer zu Horste G, Jander S, Ringelstein M, Aktas O, Kieseier B, Hartung H. Treatment of Neurological Autoimmune Disorders with Rituximab - A 7 Years Single Center Experience (P04.140) Neurology. 78: P04.140-P04.140. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P04.140 |
0.383 |
|
| 2011 |
Menge T, Hartung HP, Kieseier BC. Neutralizing antibodies in interferon beta treated patients with multiple sclerosis: knowing what to do now : Commentary to: 10.1007/s00415-010-5844-5 "One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients" by S. Malucchi et al. Journal of Neurology. 258: 904-7. PMID 21340521 DOI: 10.1007/S00415-011-5941-0 |
0.437 |
|
| 2011 |
Lalive PH, Häusler MG, Maurey H, Mikaeloff Y, Tardieu M, Wiendl H, Schroeter M, Hartung HP, Kieseier BC, Menge T. Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children Multiple Sclerosis Journal. 17: 297-302. DOI: 10.1177/1352458510389220 |
0.377 |
|
| 2010 |
Kalluri SR, Illes Z, Srivastava R, Cree B, Menge T, Bennett JL, Berthele A, Hemmer B. Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Archives of Neurology. 67: 1201-8. PMID 20937947 DOI: 10.1001/Archneurol.2010.269 |
0.324 |
|
| 2010 |
Sominanda A, Lundkvist M, Fogdell-Hahn A, Hemmer B, Hartung HP, Hillert J, Menge T, Kieseier BC. Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta. Archives of Neurology. 67: 1095-101. PMID 20837854 DOI: 10.1001/Archneurol.2010.218 |
0.336 |
|
| 2010 |
Sellner J, Cepok S, Kalluri SR, Nestler A, Kleiter I, Kümpfel T, Linker R, Melms A, Menge T, Tumani H, Paul F, Hemmer B, Berthele A. Aquaporin 4 antibody positive central nervous system autoimmunity and multiple sclerosis are characterized by a distinct profile of antibodies to herpes viruses. Neurochemistry International. 57: 662-7. PMID 20705110 DOI: 10.1016/J.Neuint.2010.08.003 |
0.383 |
|
| 2010 |
Warnke C, Menge T, Hartung HP, Racke MK, Cravens PD, Bennett JL, Frohman EM, Greenberg BM, Zamvil SS, Gold R, Hemmer B, Kieseier BC, Stüve O. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Archives of Neurology. 67: 923-30. PMID 20697042 DOI: 10.1001/Archneurol.2010.161 |
0.42 |
|
| 2010 |
Wolf C, Menge T, Stenner MP, Meyer zu Hörste G, Saleh A, Hartung HP, Wiendl H, Kieseier BC. Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy. Archives of Neurology. 67: 881-3. PMID 20625098 DOI: 10.1001/Archneurol.2010.143 |
0.344 |
|
| 2009 |
Menge T, Schloot NC, Schott M, Hemmer B, Wiendl H, Roden M, Hartung HP, Kieseier BC. Interferon beta treatment does not induce organ-specific autoantibodies in multiple sclerosis Neurology. 73: 900-902. PMID 19752459 DOI: 10.1212/Wnl.0B013E3181B78460 |
0.424 |
|
| 2009 |
Stüve O, Leussink VI, Fröhlich R, Hemmer B, Hartung HP, Menge T, Kieseier BC. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis. Archives of Neurology. 66: 259-61. PMID 19204165 DOI: 10.1001/Archneurol.2008.551 |
0.349 |
|
| 2009 |
Menge T, Büdingen HC, Dalakas MC, Kieseier BC, Hartung HP. Targeting B cells in multiple sclerosis. Current concepts and strategies | B-zell-gerichtete multiple-sklerose-therapie. Aktueller stand Nervenarzt. 80: 190-198. PMID 19189075 DOI: 10.1007/S00115-008-2664-2 |
0.372 |
|
| 2008 |
Menge T, Weber MS, Hemmer B, Kieseier BC, von Büdingen HC, Warnke C, Zamvil SS, Boster A, Khan O, Hartung HP, Stüve O. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs. 68: 2445-68. PMID 19016573 DOI: 10.2165/0003495-200868170-00004 |
0.401 |
|
| 2008 |
Stüve O, Bennett JL, Hemmer B, Wiendl H, Racke MK, Bar-Or A, Hu W, Zivadinov R, Weber MS, Zamvil SS, Pacheco MF, Menge T, Hartung HP, Kieseier BC, Frohman EM. Pharmacological treatment of early multiple sclerosis. Drugs. 68: 73-83. PMID 18081373 DOI: 10.2165/00003495-200868010-00005 |
0.398 |
|
| 2007 |
Menge T, Kieseier BC, Nessler S, Hemmer B, Hartung HP, Stüve O. Acute disseminated encephalomyelitis: an acute hit against the brain. Current Opinion in Neurology. 20: 247-54. PMID 17495616 DOI: 10.1097/Wco.0B013E3280F31B45 |
0.394 |
|
| 2007 |
Bulat K, Cepok S, von Geldern G, Hochgesand S, Menge T, Nessler S, Hartung H, Hemmer B. Combining capture ELISA and in vivo MxA test to detect neutralizing antibodies to interferon-beta in a large cohort of multiple sclerosis patients Aktuelle Neurologie. 34. DOI: 10.1055/S-2007-987508 |
0.343 |
|
| 2006 |
Lalive PH, Menge T, Barman I, Cree BA, Genain CP. Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays Neurology. 67: 176-177. PMID 16832107 DOI: 10.1212/01.Wnl.0000223346.09426.34 |
0.382 |
|
| 2006 |
Menge T, von Buedingen H, Lalive P, Genain C. Sa.34. Marmoset Derived Anti-Myelin Fab Fragments That Uniquely Stain Within Multiple Sclerosis Lesions Clinical Immunology. 119: S117. DOI: 10.1016/J.Clim.2006.04.266 |
0.309 |
|
| 2005 |
Menge T, Hemmer B, Nessler S, Wiendl H, Neuhaus O, Hartung HP, Kieseier BC, Stüve O. Acute disseminated encephalomyelitis: an update. Archives of Neurology. 62: 1673-80. PMID 16286539 DOI: 10.1001/Archneur.62.11.1673 |
0.352 |
|
| 2005 |
Menge T, Hartung HP, Stüve O. Statins--a cure-all for the brain? Nature Reviews. Neuroscience. 6: 325-31. PMID 15803163 DOI: 10.1038/Nrn1652 |
0.324 |
|
| Show low-probability matches. |